Clinical efficacy of ruxolitinib monotherapy and haploidentical hematopoeitic stem cell transplantation in a child with philadelphia chromosome-like relapsed/refractory acute lymphoblastic leukemia

dc.authorid0000-0002-9688-5223
dc.authorid0000-0002-9710-8653
dc.authorid0000-0002-7129-5024
dc.authorid0000-0003-0037-7636
dc.authorid0000-0002-4551-5433
dc.authorid0000-0002-7424-8688
dc.authorid0000-0002-0476-5452
dc.authorid0000-0001-9629-0783
dc.authorid0000-0001-8489-7449
dc.contributor.authorBayram, Nihan
dc.contributor.authorYaman, Yöntem
dc.contributor.authorÖzdilli, Kürşat
dc.contributor.authorTelhan, Leyla
dc.contributor.authorNepesov, Serdar
dc.contributor.authorBilgen, Hülya
dc.contributor.authorElli, Murat
dc.contributor.authorBehar, Sude Sema
dc.contributor.authorAnak, Sema
dc.date.accessioned2021-10-11T08:19:24Z
dc.date.available2021-10-11T08:19:24Z
dc.date.issued2021
dc.departmentİstanbul Medipol Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Çocuk Sağlığı ve Hastalıkları Ana Bilim Dalı
dc.departmentİstanbul Medipol Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıkları Ana Bilim Dalı
dc.description.abstractIntroduction (Ph-like) ALL is a subset of leukemia which has a gene expression profile similar to Ph+disease, but without the presence of BCR-ABL1 translocation. Case description We reported an exceptional case of a child with relapsed Ph-like ALL with IKZF1 gene deletion treated with high-dose ruxolitinib as monotherapy, after multi-agent chemotherapy. He remains in continued MRD-negative leukemia remission with full donor chimerism at 12 months post-HSCT. Discussion The circumstance that makes our case featured is the usage of ruxolitinib as monotherapy. This report, we believe, is a pioneering report for a frequent disease with a high risk of failure for the outcome.
dc.identifier.citationBayram, N., Yaman, Y., Özdilli, K., Telhan, L., Nepesov, S., Bilgen, H. ... Anak, S. (2021). Clinical efficacy of ruxolitinib monotherapy and haploidentical hematopoeitic stem cell transplantation in a child with philadelphia chromosome-like relapsed/refractory acute lymphoblastic leukemia. Pediatric Transplantation, 25(4). https://dx.doi.org/10.1111/petr.14024
dc.identifier.doi10.1111/petr.14024
dc.identifier.issn1397-3142
dc.identifier.issn1399-3046
dc.identifier.issue4
dc.identifier.scopusqualityQ2
dc.identifier.urihttps://dx.doi.org/10.1111/petr.14024
dc.identifier.urihttps://hdl.handle.net/20.500.12511/8410
dc.identifier.volume25
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherWiley
dc.relation.ispartofPediatric Transplantationen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/embargoedAccess
dc.subjectJAK Inhibitors
dc.subjectPhiladelphia-Like ALL
dc.subjectRefractory ALL
dc.subjectStem Cell Transplantation
dc.titleClinical efficacy of ruxolitinib monotherapy and haploidentical hematopoeitic stem cell transplantation in a child with philadelphia chromosome-like relapsed/refractory acute lymphoblastic leukemia
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
Yaman-Yontem-2021.pdf
Boyut:
412.49 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama: